She credits her friends and family for introducing her to the Oncotype DX DCIS test.
Throughout her Ductal Carcinoma in Situ (DCIS) treatment journey, Jen was lucky to have support from her Yale Women’s Crew teammates, and her close friends and family – whom she credits for introducing her to the Oncotype DX DCIS test. Upon sharing her DCIS diagnosis with her family, one of her relatives, a pathologist at John Hopkins, suggested she speak to her doctor about Oncotype DX test for DCIS patients, as he felt it would be an important data point as she considered treatment options, and her doctors agreed.
"The Oncotype DX DCIS test was a CRITICAL piece of data that helped keep me moving forward in my own process. Being given personalized information specific to my tumor allowed me to move ahead confidently."
“"For me the Oncotype DX DCIS test was a key piece of evidence, which confirmed my decision to have a double-mastectomy.”
A busy mother of two and active community volunteer, Jen is passionate about making other patients aware of the Oncotype DX DCIS test, so that they too can base their treatment decisions on the underlying biology of their individual tumors.
"For me the Oncotype DX DCIS test was a key piece of evidence, which confirmed my decision to have a double-mastectomy. I want every patient to have access to this test and the peace of mind that comes with it."
Back to Featured Stories